VAQTA
Biological
Merck Sharp & Dohme Corporation
Total Payments
$98,532
Transactions
1,158
Doctors
1,049
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $68,035 | 28 | 26 |
| 2023 | $5,539 | 325 | 309 |
| 2022 | $165.60 | 10 | 10 |
| 2021 | $502.40 | 31 | 31 |
| 2020 | $17,505 | 460 | 435 |
| 2019 | $4,508 | 295 | 287 |
| 2018 | $60.97 | 6 | 6 |
| 2017 | $2,216 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $67,476 | 1 | 68.5% |
| Food and Beverage | $18,094 | 1,145 | 18.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,080 | 5 | 9.2% |
| Space rental or facility fees (teaching hospital only) | $2,700 | 3 | 2.7% |
| Travel and Lodging | $1,182 | 4 | 1.2% |
Payments by Type
Research
$67,476
1 transactions
General
$31,056
1,157 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 32-Year Persistence of Hepatitis A Antibody among Participants in the Pivotal, Double-Blind, Placebo-Controlled Efficacy Study of VAQTA Hepatitis A Vaccine, Study 023-001 | Merck Sharp & Dohme LLC | $67,476 | 0 |
Top Doctors Receiving Payments for VAQTA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Newport, RI | $70,176 | 4 |
| , M.D | Infectious Disease | Louisville, KY | $7,122 | 7 |
| , M.D | Geriatric Medicine | Laguna Hills, CA | $1,570 | 1 |
| , MD | Family Medicine | Buffalo, NY | $1,570 | 1 |
| , M.D | Allergy & Immunology | Henderson, NV | $59.00 | 3 |
| , MD | Internal Medicine | Macon, GA | $58.19 | 4 |
| , D.O | Pediatrics | Henderson, NV | $48.62 | 2 |
| , MD | Pediatrics | Metairie, LA | $47.32 | 3 |
| , M.D | Pediatrics | Wichita, KS | $46.07 | 3 |
| , MD | Pediatrics | Camden, NJ | $45.16 | 3 |
| , MD | Obstetrics & Gynecology | Macon, GA | $44.70 | 3 |
| , MD | Pediatrics | Detroit, MI | $44.03 | 2 |
| , MD | Pediatrics | Macon, GA | $43.36 | 3 |
| , M.D | Pediatrics | Macon, GA | $43.36 | 3 |
| , MD | Pediatrics | San Antonio, TX | $41.65 | 2 |
| , M.D | Pediatrics | Garden Grove, CA | $41.24 | 2 |
| , M.D | Pediatrics | Waldorf, MD | $39.83 | 2 |
| , DO | Pediatrics | Bowling Green, OH | $39.27 | 2 |
| , M.D | Pediatrics | Fountain Valley, CA | $38.76 | 2 |
| , M.D | Pediatrics | White Plains, NY | $38.37 | 2 |
| , M.D | Pediatrics | White Plains, NY | $38.37 | 2 |
| , M.D | Pediatrics | White Plains, NY | $38.37 | 2 |
| , MD | Pediatrics | Woodmere, NY | $38.10 | 2 |
| , M.D | Pediatrics | Bethlehem, PA | $37.83 | 2 |
| , NP | Family | Los Angeles, CA | $37.49 | 2 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme LLC $73,739
- Merck Sharp & Dohme Corporation $24,793
Product Information
- Type Biological
- Total Payments $98,532
- Total Doctors 1,049
- Transactions 1,158
About VAQTA
VAQTA is a biological associated with $98,532 in payments to 1,049 healthcare providers, recorded across 1,158 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $68,035 was paid across 28 transactions to 26 doctors.
The most common payment nature for VAQTA is "Unspecified" ($67,476, 68.5% of total).
VAQTA is associated with 1 research study, including "32-Year Persistence of Hepatitis A Antibody among Participants in the Pivotal, Double-Blind, Placebo-Controlled Efficacy Study of VAQTA Hepatitis A Vaccine, Study 023-001" ($67,476).